GuidelineThe Canadian journal of cardiology2006
Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease.
Guideline in The Canadian journal of cardiology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It reports registered trial NCT00458055. Cited by 104 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treatment Study for Severe High-Density Lipoprotein Deficiency
Open the trial in the graphWho cites it
104 citing papers in PubMed, 4 syntheses or guidelines pooled it, 309 citations in OpenAlex.
- Effect of sleep surgery on lipid profiles in adults with obstructive sleep apnea: a meta-analysis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2022Pooled it
- Associations of job strain and lifestyle risk factors with risk of coronary artery disease: a meta-analysis of individual participant data.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2013Pooled it
- Osteoporosis Canada 2010 guidelines for the assessment of fracture risk.Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes · 2011Guideline
- The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2008Pooled it
- Communication and patient participation influencing patient recall of treatment discussions.Health expectations : an international journal of public participation in health care and health policy · 2017Trial
- Prevalence of normal weight central obesity among Thai healthcare providers and their association with CVD risk: a cross-sectional study.Scientific reports · 2016Trial
- Impact of daily Chlorella consumption on serum lipid and carotenoid profiles in mildly hypercholesterolemic adults: a double-blinded, randomized, placebo-controlled study.Nutrition journal · 2014Trial
- Impact of the ENHANCE trial on the use of ezetimibe in the United States and Canada.American heart journal · 2014 · on this mapTrial
- Assessment of the Siksika chronic disease nephropathy-prevention clinic.Canadian family physician Medecin de famille canadien · 2013Trial
- Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study.Diabetes care · 2012Trial
- A cluster randomized controlled Trial to Evaluate an Ambulatory primary care Management program for patients with dyslipidemia: the TEAM study.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2010 · on this mapTrial
- Achieving cholesterol targets by individualizing starting doses of statin according to baseline low-density lipoprotein cholesterol and coronary artery disease risk category: the CANadians Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (CanACTFAST) study.The Canadian journal of cardiology · 2010Trial
- The Enhancing Secondary Prevention in Coronary Artery Disease trial.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2009Trial
- Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial.The Canadian journal of cardiology · 2009Trial
- Efficacy of alternate day versus daily dosing of rosuvastatin.The Canadian journal of cardiology · 2009Trial
- Statins but not fibrates improve the atherogenic to anti-atherogenic lipoprotein particle ratio: a randomized crossover study.BMC clinical pharmacology · 2008Trial
- Association of chronic kidney disease and cardiovascular disease risk with all-cause mortality: an interaction, joint and mediation analysis in Chinese adults.BMC public health · 2025Article
- IL-6 and Cardiovascular Risk: A Narrative Review.Current atherosclerosis reports · 2024Review
- Predictive value of total cholesterol to high-density lipoprotein cholesterol ratio for chronic kidney disease among adult male and female in Northwest China.Chronic diseases and translational medicine · 2024Article
- A new predictor of coronary artery disease in acute ischemic stroke or transient ischemic attack patients: pericarotid fat density.European radiology · 2024Article
44 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the last publication of the recommendations for the management and treatment of dyslipidemia, new clinical trial data have emerged that support a more vigorous approach to lipid lowering in specific patient groups. The decision was made to update the lipid guidelines in collaboration with the Canadian Cardiovascular Society. A systematic electronic search of medical literature for original research consisting of blinded, randomized controlled trials was performed. Meta-analyses of studies of the efficacy and safety of lipid-lowering therapies, and of the predictive value of established and emerging risk factors were also reviewed. All recommendations are evidence-based, and have been reviewed in detail by primary and secondary review panels. Major changes include a lower low-density lipoprotein cholesterol (LDL-C) treatment target (lower than 2.0 mmol/L) for high-risk patients, a slightly higher intervention point for the initiation of drug therapy in most low-risk individuals (LDL-C of 5.0 mmol/L or a total cholesterol to high-density lipoprotein cholesterol ratio of 6.0) and recommendations regarding additional investigations of potential use in the further evaluation of coronary artery disease risk in subjects in the moderate-risk category.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.